The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.
Preventive Eye Care in People With Diabetes Is Cost-Saving to the Federal Government: Implications for health-care reform
Abstract
OBJECTIVE: Diabetic retinopathy, which leads to macular edema and retinal neovascularization, is the leading cause of blindness among working-age Americans. Previous research has demonstrated significant cost savings associated with detection of eye disease in Americans with type 1 diabetes. However, detection and treatment of eye disease among those with type II diabetes was previously thought not to be cost-saving. Our purpose was to estimate the current and potential federal savings resulting from the screening and treatment of retinopathy in patients with type II diabetes, based on recently availabledata concerning efficacy of treating both macular edema and neovascularization along withnew data on federal budgetary costs of blindness. RESEARCH DESIGN AND METHODS: We used computer modeling, incorporating data from population-based epidemiological studies and multicenter clinical trials. Monte Ciarlosimulation was used, combined with sensitivity analysis and present value analysis of cost savings. RESULTS: Screening and treatment for eye disease in patients with type II diabetes generates annual savings of $247.9 million to the federal budget and 53,986 person-years of sight, even at current suboptimal (60%) levels of care. If all patients with type II diabetes receive recommended care, the predicted net savings (discounted at 5%) exceeds $472.1 million and 94,304 person-years of sight. Nearly all savings areassociated with detection and treatment of diabetic macular edema. Enrolling each additional person with type II diabetes into currently recommended ophthalmological care resultsin an average net savings of $975/person, even if all costs of care are borne by the federal government. CONCLUSIONS: Our analysis indicates that prevention programs aimed at improving eye care for patients with diabetes not only reduce needless vision loss but also willprovide a financial return on the investment of public funds.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Foundations of Cost-Effectiveness Analysis for Health and Medical Practices
Weinstein, M. C., & Stason, W. B. (1977) · New England Journal of Medicine · doi:10.1056/nejm197703312961304 · Cited by 2,119
Klein, R. (1984) · Archives of Ophthalmology · doi:10.1001/archopht.1984.01040030398010 · Cited by 1,885
Onset of NIDDM occurs at Least 4–7 yr Before Clinical Diagnosis
Harris, M. I., Klein, R., Welborn, T. A., & Knuiman, M. W. (1992) · Diabetes Care · doi:10.2337/diacare.15.7.815 · Cited by 1,306
Klein, R. (1989) · Archives of Ophthalmology · doi:10.1001/archopht.1989.01070010243030 · Cited by 470
How Effective Are Treatments for Diabetic Retinopathy?
Ferris, F. L. (1993) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1993.03500100088034 · Cited by 392
Self-citationKlein, R. (1989) · Archives of Ophthalmology · doi:10.1001/archopht.1989.01070010250031 · Cited by 361
Dorman, J. S., Laporte, R. E., Kuller, L. H., Cruickshanks, K. J., Orchard, T. J., Wagener, D. K., Becker, D. J., Cavender, D. E., & Drash, A. L. (1984) · Diabetes · doi:10.2337/diab.33.3.271 · Cited by 350
Diagnosis of Diabetic Eye Disease
Sussman, E. J. (1982) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.1982.03320480047025 · Cited by 266
Moss, S. E., Klein, R., Kessler, S. D., & Richie, K. A. (1985) · Ophthalmology · doi:10.1016/s0161-6420(85)34082-4 · Cited by 245
Klein, B. E. K., Davis, M. D., Segal, P., Long, J. A., Harris, W. A., Haug, G. A., Magli, Y. L., & Syrjala, S. (1984) · Ophthalmology · doi:10.1016/s0161-6420(84)34336-6 · Cited by 241
Cited by
Ranibizumab for Diabetic Macular Edema
Nguyen, Q. D., Brown, D. M., Marcus, D. M., Boyer, D. S., Patel, S., Feiner, L., Gibson, A., Sy, J., Rundle, A. C., Hopkins, J. J., et al. (2012) · Ophthalmology · doi:10.1016/j.ophtha.2011.12.039 · Cited by 1,621
Prevalence of Diabetic Retinopathy in the United States, 2005-2008
Zhang, X., Saaddine, J. B., Chou, C.-F., Cotch, M. F., Cheng, Y. J., Geiss, L. S., Gregg, E. W., Albright, A. L., Klein, B. E. K., & Klein, R. (2010) · JAMA · doi:10.1001/jama.2010.1111 · Cited by 1,196
Ting, D. S. W., Cheung, G. C. M., & Wong, T. Y. (2016) · Clinical & Experimental Ophthalmology · doi:10.1111/ceo.12696 · Cited by 1,066
Fong, D. S., Aiello, L. P., Ferris, F. L., & Klein, R. (2004) · Diabetes Care · doi:10.2337/diacare.27.10.2540 · Cited by 640
Self-citationFone, D., Hollinghurst, S., Temple, M., Round, A., Lester, N., Weightman, A., Roberts, K., Coyle, E., Bevan, G., & Palmer, S. (2003) · Journal of Public Health · doi:10.1093/pubmed/fdg075 · Cited by 553
Metadata
- Authors
- Javitt, J. C., Aiello, L. P., Chiang, Y., Ferris, F. L., Canner, J. K., & Greenfield, S.
- Venue
- Diabetes Care
- Publisher
- American Diabetes Association
- Published
- 1994-08-01
- Volume
- 17
- Issue
- 8
- Pages
- 909-917
- ISSN
- 0149-5992 (ISSN-L)
- 1935-5548
- OpenAlex
- W1986954767
- Cited by
- 364
- References
- 25
- FWCI
- 10.90
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Preventive Eye Care in People With Diabetes Is Cost-Saving to the Federal Government: Implications for health-care reform. https://app.cochat.ai/papers/10.2337/diacare.17.8.909
- The paper
- Javitt, J. C., Aiello, L. P., Chiang, Y., Ferris, F. L., Canner, J. K., & Greenfield, S. (1994). Preventive Eye Care in People With Diabetes Is Cost-Saving to the Federal Government: Implications for health-care reform. Diabetes Care. https://doi.org/10.2337/diacare.17.8.909
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
